Wire · opportunities
How 1st FDA approved once-a-day pill to lower 'bad' cholesterol could shift treatment from statins
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 July 2026 · Fusion42 review
The FDA has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor pill for lowering LDL cholesterol, offering a pill-based alternative to injectable cholesterol treatments for patients whose cholesterol remains high despite statins. The drug reduced LDL by 56-59% in trials and targets high-risk patients including those with diabetes, inherited hypercholesterolaemia, and prior heart disease.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're building adherence tools, compliance software, or patient engagement platforms for chronic disease, you just watched a category (injectable cholesterol drugs) become a tablet category. Merck's shift from injection to pill on a proven molecule is a playbook: find where needle anxiety or inconvenience kills adoption, then solve it with formulation. That gap is your wedge.
◆ Coverage
1 source · 18 Jul 2026
◆ Related on Wire
◆ Topics